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c o n c i s e c o m m u n i c a t i o n
Discontinuation of Reflex Testing of
Stool Samples for Vancomycin-Resistant
Enterococci Resulted in Increased
Prevalence
Mandy Bodily, RN, MPH, CIC;1
Kathleen M. McMullen, MPH, CIC;1
Anthony J. Russo, MPH;1 Nupur D. Kittur, PhD, MPH;2
Joan Hoppe-Bauer, BS;3 David K. Warren, MD, MPH2
Discontinuation of reflex testing of stool submitted for Clostridium
difficile testing for vancomycin-resistant enterococci (VRE) led to
an increase in the number of patients with healthcare-associated
VRE bacteremia and bacteriuria (0.21 vs 0.36 cases per 1,000 patient-
days; ). Cost-benefit analysis showed reflex screening and iso-P ! .01
lation of VRE reduced hospital costs.
Infect Control Hosp Epidemiol 2013;34(8):838-840
Vancomycin-resistant enterococci (VRE) cause infections that
result in increased cost and hospital length of stay.1 Earlier
studies have reported a substantial proportion of patients with
Clostridium difficile infection who are cocolonized with
VRE.2,3 On the basis of these data, a “reflex” testing program
was initiated at our hospital in the 1990s to limit VRE trans-
mission. Reflex testing was a policy whereby any stool sub-
mitted to the laboratory for C. difficile toxin testing from an
inpatient was also tested for VRE using selective media (VRE
Agar; Remel). Patients identified by reflex testing, routine
clinical culture, or records from an outside facility as being
VRE colonized or infected were placed under contact pre-
cautions.
In 2010, concerns were raised about the cost benefit of
reflex testing. Healthcare-associated VRE rates both within
the hospital and nationally over the previous decade had been
stable.4,5 On the basis of a lack of clear evidence that it was
affecting VRE epidemiology, reflex testing was discontinued.
The purpose of this study is to examine the effect of discon-
tinuation of this VRE reflex testing program on healthcare-
associated VRE transmission.
methods
Barnes-Jewish Hospital is a 1,250 bed academic tertiary care
hospital in Saint Louis, Missouri. There are 1,160 patient
rooms, of which 741 can be semi-private. Hospital policy is
to place patients with VRE colonization or infection under
contact precautions in a private room. Reflex testing for VRE
was discontinued in July 2010. Physicians were notified of
this change. Clinicians could still order stool or perirectal
cultures for VRE testing at their discretion. No additional
interventions targeting VRE were implemented at the time.
To determine the effect of discontinuing reflex testing on
VRE transmission, the healthcare-associated VRE rate was
evaluated from January 2009 to December 2011. All hospi-
talized patients with a urine or blood culture positive for VRE
were identified. A healthcare-associated VRE case was defined
as the first positive specimen per patient for whom VRE was
detected in blood or urine more than 48 hours after admis-
sion. A VRE case was considered present at admission if VRE
first was detected in blood or urine 48 hours or less after
admission. VRE cases were expressed per 1,000 patient-days.
Rate trends were evaluated using interrupted time series
modeling (SPSS, ver 18.0; IBM SPSS). Segmented regression
analysis was performed to assess the effect of the discontin-
uing VRE reflex testing on healthcare-associated VRE rates.6
We hypothesized that there would be a delay between dis-
continuation of the testing and resulting change in acquisition
rates, because the effect of increased colonization pressure
would not be immediately seen.7 Therefore, we used a 1-
month delay for evaluating the post-discontinuation segment.
Monthly VRE prevalence at hospital admission was included
in the model to account for any change during the study
period. Institutional review board approval was obtained
from Washington University.
results
In the 18 months before discontinuation of reflex testing,
9,652 stool specimens underwent VRE testing (mean, 536
stool specimens per month). In the 18 months after reflex
testing was stopped, 2,974 stool specimens were tested (mean,
165 stool specimens per month; a 69% decrease; ).P ! .01
The monthly mean number of patients with a VRE-positive
stool culture decreased from 136 to 45 (a 67% decrease;
).P ! .01
There were 92 cases of healthcare-associated VRE during
433,855 patient-days (0.21 cases per 1,000 patient-days) in
the reflex testing period compared with 159 cases in the
444,092 patient-days after discontinuation (0.36 cases per
1,000 patient-days; Figure 1). The full regression model
showed no baseline trend in healthcare-associated VRE
( ) and no trend change after discontinuation of re-P p .772
flex testing ( ). There was no significant trend in ratesP p .727
of VRE present at hospital admission (0.16 cases per 1,000
patient-days before discontinuation vs 0.22 cases per 1,000
patient-days after discontinuation; ). There was aP p .704
significant change in the y-intercept, with the monthly health-
care-associated VRE rate increasing by 0.17 cases per 1,000
patient-days ( ) when VRE reflex testing wasP p .04
discontinued.
The cost-benefit analysis was completed for the first 12
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figure 1. Monthly incidence of healthcare-associated vancomycin-resistant enterococci (VRE), January 2009–December 2011. pt, patient.
months after discontinuation. Assuming reflex testing had
been continued and the rate of healthcare-associated VRE
was the same as the preintervention rate, we would have
expected 14 fewer patients with VRE bacteremia and 26 fewer
patients with bacteriuria. During the discontinuation period,
the institution saved $20,920 in laboratory costs ($4 per VRE
test, 5,230 fewer tests). Isolation bed avoidance saved ap-
proximately $95,788 ($77 per isolation bed-day, 1,244 fewer
days of VRE isolation). On the basis of estimates in the lit-
erature, the cost of treating the excess cases of VRE bacteremia
was approximated at $139,286 ($9,949 per case of bacteremia,
14 excess cases of bacteremia), resulting in an excess cost of
at least $22,578 per year without reflex testing.1
conclusion
The role of routine active surveillance in the control of
antimicrobial-resistant organisms in hospitals remains un-
clear.8,9 Previous studies have demonstrated the benefit of
active surveillance cultures to control VRE transmission in
hospitals; however, these were generally done during an out-
break in which multiple interventions were introduced si-
multaneously.10,11 We found that discontinuation of reflex
VRE testing of stool submitted for testing for C. difficile re-
sulted in an approximately 71% increase in the endemic
healthcare-associated VRE rate. Strengths of the study include
that no other infection prevention measures were imple-
mented when reflex testing was stopped and that the VRE
rate was stable before discontinuation. We hypothesize that
the discontinuation of VRE reflex testing resulted in decreased
identification and isolation of patients with VRE colonization,
which resulted in increased VRE colonization pressure
throughout the hospital and a subsequent increased risk of
VRE transmission.
The cost of laboratory testing was a consideration in the
decision to discontinue the VRE reflex testing program. Mi-
crobiological cultures performed for inpatients for the pur-
pose of screening cannot be submitted to Medicare for re-
imbursement. Therefore, the cost of active surveillance must
be absorbed by the facility. Our cost analysis suggests that
savings gained from reduced laboratory and isolation bed cost
were nullified by the increased cost of treating patients with
VRE bacteremia.
There are limitations to this study. We used a quasi-
experimental study design. Therefore, we cannot rule out the
possibility that unmeasured variables, such as underlying pa-
tient characteristics, may have changed during the study pe-
riod and affected our findings. The VRE rate increased when
reflex testing was discontinued even after controlling the data
for incoming colonization pressure (ie, patients who had VRE
detected in blood or urine within 48 hours of admission).
Laboratory methods for identifying VRE from urine and
blood cultures did not change during the study period. This
study was done in a large academic medical facility, and the
results may not be generalizable to other healthcare facilities
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with differing endemic VRE rates. We did not determine the
cost associated with the treatment of VRE infections other
than bacteremia, although we would anticipate that these
would further increase the benefits of reflex testing. Finally,
we examined cost from a hospital, rather than societal, per-
spective, although hospitals bear the direct cost of an active
surveillance program.
In conclusion, we found that discontinuation of reflex test-
ing of stool specimens submitted to the laboratory for C.
difficile testing for VRE resulted in a hospitalwide increase in
cases of healthcare-associated VRE and was not cost effective.
On the basis of these results, reflex testing was reinstituted
at our facility. Additional studies in a variety of healthcare
facilities are needed to determine whether this screening strat-
egy is effective in other settings.
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